BioMarin
Trade BioMarin 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BMRN
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.
BMRN Key Statistics
Stock Snapshot
As of today, BioMarin(BMRN) shares are valued at $60.88. The company's market cap stands at 11.75B, with a P/E ratio of 22.91.
On 2025-12-20, BioMarin(BMRN) stock moved within a range of $50.12 to $63.89. With shares now at $60.88, the stock is trading +21.5% above its intraday low and -4.7% below the session's peak.
Trading volume for BioMarin(BMRN) stock has reached 18.34M, versus its average volume of 3.74M.
Over the past 52 weeks, BioMarin(BMRN) stock has traded between a high of $73.51 and a low of $50.12.
Over the past 52 weeks, BioMarin(BMRN) stock has traded between a high of $73.51 and a low of $50.12.
BMRN News
BioMarin Pharmaceutical (BMRN) has quietly staged a double digit rebound over the past month, even though the longer term chart still shows steep drawdowns that...
William Blair analyst Sami Corwin notes Market Perform-rated BioMarin (BMRN) announced that it will acquire Amicus Therapeutics (FOLD) for $14.50 per share in a...
BioMarin (BMRN) is up 21.4%, or $11.13 to $63.08. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investin...
Analyst ratings
74%
of 27 ratingsMore BMRN News
In trading on Friday, shares of BioMarin Pharmaceutical Inc (Symbol: BMRN) crossed above their 200 day moving average of $57.99, changing hands as high as $63.8...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares are trading higher on Friday after the companies penned a merger d...
Yun Zhong, an analyst from Wedbush, maintained the Buy rating on BioMarin Pharmaceutical. The associated price target remains the same with $94.00. Claim 50% Of...
BioMarin Pharmaceutical (BMRN) and Amicus (FOLD) stocks soared on Friday after the two medical companies announced an acquisition agreement. Under the terms of...
Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...
How BioMarin's $270 Million Takeover Led This Dollar Stock To A Triple-Digit Gain 5/16/2025 BioMarin said Friday it would spend $270 million to acquire Inozyme...
(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN), a pharmaceutical company, Friday announced that it has entered into a definitive agreement to acquire Amicus Th...